TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 ( TLR7 ) agonist with a LEC of 0.4 μM.
In Vitro
TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a lowest effective concentration (LEC) of 0.4 μM in HEK293 cell. TLR7 agonist 2 is found to be selective for TLR7 over TLR8 with LEC of >100 μM for human TLR8. TLR7 agonist 2 demonstrates low inhibition across five CYP450 isozymes (IC 50 >10 μM) and is also not a time dependent inhibitor of CYP450 3A4. TLR7 agonist 2 has limited inhibition of the hERG potassium ion channel 3 H-dofetilide binding in vitro (IC 50 >50 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
TLR7 agonist 2 is found to be rapidly cleared in conjunction with our target profile. Both C max and AUC increase less than dose proportionally between 0.3 and 3 mg/kg and more than dose-proportionally between 3 and 10 mg/kg. TLR7 agonist 2 can induce an antiviral interferon stimulated gene (ISG) response without inducing an IFNα response at a low dose. TLR7 agonist 2 also induces a 2.7 log decrease in serum HBV viral load from 0.3 mg/kg, and a maximum 3.1 log decrease is observed for doses between 1 and 5 mg/kg . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
